Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

19.68 +0.85 (+4.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China
From Summit Therapeutics Inc.
Via Business Wire
News headline image
This Company's Co-CEOs Just Bought More Shares. Should You? ↗
Via The Motley Fool
News headline image
In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio? ↗
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences. 
Via Benzinga
News headline image
Top 3 Health Care Stocks You May Want To Dump This Quarter ↗
 
Via Benzinga
News headline image
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX ↗
Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025. 
Via Stocktwits
Topics Animal Testing
News headline image
Gold Related Large-Cap Stocks Outperformed In One Of The Most Volatile Weeks (Apr 7-Apr 11): Are These In Your Portfolio? ↗
Last week's top performers: SMMT, HMY, AU, CVNA, HOOD, NEM, AVGO, GFI, KGC, CEG. Are they in your portfolio? #stockmarket #investing 
Via Benzinga
News headline image
3 Magnificent Stocks That Could Double or More by 2030 ↗
Via The Motley Fool
News headline image
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets ↗
Via The Motley Fool
Topics ETFs
News headline image
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade ↗
Via The Motley Fool
Topics Government
News headline image
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months ↗
Via The Motley Fool
Topics Artificial Intelligence Economy World Trade
News headline image
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today ↗
Via The Motley Fool
Topics Government World Trade
News headline image
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades. ↗
Via The Motley Fool
Topics Intellectual Property Retirement
News headline image
Why Summit Therapeutics Stock Slipped Today ↗
Via The Motley Fool
News headline image
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics ↗
Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space. 
Via Benzinga
News headline image
Is Summit Therapeutics a Millionaire Maker? ↗
Via The Motley Fool
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
News headline image
This Unstoppable Biotech Stock Just Became an Even Better Buy ↗
Via The Motley Fool
News headline image
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? ↗
Top 10 large-cap stocks rose last week: Rubrik 23.17%, Applovin 17.21%, Summit Therapeutics 16.93%, Intel 16.52%, VG 16.03%, GE Vernova 14.01%, Samsara 11.96%, Antero Resources 11.68%, Super Micro... 
Via Benzinga
News headline image
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Why Summit Therapeutics Stock Was Winning This Week ↗
Via The Motley Fool
News headline image
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year ↗
Via The Motley Fool
News headline image
2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger ↗
Via The Motley Fool
News headline image
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown ↗
Message volume on Stocktwits jumped 2,500%, with retail traders focusing on Summit’s partnership to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates for solid tumors. 
Via Stocktwits
News headline image
Palantir Extends Losses, Microsoft Slides: What's Driving Markets Monday? ↗
The major indices struggled to maintain early momentum on Monday, but appear to climbing back with the S&P 500 and Dow Jones both green in midday trading.  
Via Benzinga
Topics Stocks
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 24, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.